Citizens Jmp Raises Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00

Halozyme Therapeutics (NASDAQ:HALO) had its price objective boosted by Citizens Jmp from $92.00 to $93.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp’s price objective would indicate a potential downside of 6.23% from the stock’s current price.

Several other equities analysts have also recently issued reports on the company. HC Wainwright boosted their price objective on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a report on Friday. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 31st. UBS Group reaffirmed a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $89.70.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $13.42 during trading hours on Friday, hitting $99.18. The company’s stock had a trading volume of 3,173,590 shares, compared to its average volume of 1,802,641. The stock has a market cap of $11.76 billion, a PE ratio of 35.61, a price-to-earnings-growth ratio of 0.35 and a beta of 0.85. Halozyme Therapeutics has a 12-month low of $61.22 and a 12-month high of $100.31. The company has a 50 day moving average of $75.74 and a 200 day moving average of $71.25. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter last year, the company posted $1.54 earnings per share. The firm’s revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts forecast that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. This represents a 33.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the transaction, the director owned 42,044 shares in the company, valued at $3,225,195.24. This trade represents a 3.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 72,477 shares of company stock worth $5,102,643. 2.50% of the stock is owned by corporate insiders.

Institutional Trading of Halozyme Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Norges Bank acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter worth approximately $128,201,000. William Blair Investment Management LLC purchased a new position in Halozyme Therapeutics in the 4th quarter valued at $124,031,000. Voloridge Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at about $77,587,000. Qube Research & Technologies Ltd purchased a new stake in Halozyme Therapeutics during the 2nd quarter valued at about $51,295,000. Finally, Assenagon Asset Management S.A. raised its holdings in Halozyme Therapeutics by 4,578.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company’s stock valued at $78,086,000 after acquiring an additional 976,321 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Strong Q2 results: Halozyme reported adjusted EPS of $2.28, above the roughly $1.79-$1.82 consensus range, while revenue reached $481 million versus estimates of approximately $402 million. Revenue increased 48% year over year, and royalty revenue rose 50% to $308 million. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Raised full-year guidance: The company now expects 2026 revenue of $1.835 billion-$1.910 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS outlook is above the approximately $8.02 analyst consensus, signaling stronger expected profitability and growth.
• Positive Sentiment: Additional collaboration momentum: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s recurring royalty and licensing growth strategy. Halozyme Collaboration Agreements
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO from “market perform” to “outperform” with a $110 price target. HC Wainwright also raised its target from $95 to $115 and maintained a “buy” rating, implying substantial upside from the current trading level. Benzinga Analyst Actions
• Neutral Sentiment: The company’s earnings-call presentation and transcript provide additional details on the quarter, collaboration pipeline and operating outlook. Q2 2026 Earnings Presentation

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.